DMAA — Drugs Made In America Acquisition Corp.
Price · 2025-02-25 → 2026-08-21
375 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2025-02-25.
Performance
Technicals
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2025-02-18 | Drugs Made In America Acquisition LLC | Open-market purchase | 30.0K | — | — |
| 2025-02-18 | Stockwell Lynn CEO and Exe. Chair of Board | Open-market purchase | 30.0K | — | — |
| 2025-01-29 | Drugs Made In America Acquisition LLC | Open-market purchase | 400.0K | — | — |
| 2025-01-29 | Drugs Made In America Acquisition LLC | Open-market sale | 5.7M | — | — |
| 2025-01-29 | Drugs Made In America Acquisition LLC | Other Acquisition/Disposition | 400.0K | — | — |
| 2025-01-29 | Stockwell Lynn CEO and Executive COB | Open-market sale | 5.7M | — | — |
| 2025-01-29 | Stockwell Lynn CEO and Executive COB | Other Acquisition/Disposition | 400.0K | — | — |
| 2025-01-29 | Stockwell Lynn CEO and Executive COB | Open-market purchase | 400.0K | — | — |
| 2025-01-29 | Worman Glenn C. CFO | Other Acquisition/Disposition | 100.0K | — | — |
| 2025-01-29 | Do Catherine Director | Other Acquisition/Disposition | 100.0K | — | — |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Karpus Management, Inc. | 26.5M | 2.5M |
| First Trust Capital Management L.P. | 23.5M | 2.2M |
| MIZUHO SECURITIES USA LLC | 20.9M | 2.0M |
| Westchester Capital Management, LLC | 17.5M | 1.7M |
| Polar Asset Management Partners Inc. | 16.8M | 1.6M |
| WOLVERINE ASSET MANAGEMENT LLC | 16.3M | 1.6M |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 13.9M | 1.3M |
| ARISTEIA CAPITAL, L.L.C. | 9.2M | 881.7K |
| D. E. Shaw & Co., Inc. | 7.2M | 690.0K |
| HEIGHTS CAPITAL MANAGEMENT, INC | 6.8M | 650.0K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-13 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-13 | — | on EDGAR ↗ |
| 425 | 2026-07-20 | — | on EDGAR ↗ |
| 8-K | 2026-07-20 | 2026-07-14 | on EDGAR ↗ |
| SCHEDULE 13G | 2026-06-26 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Drugs Made In America Acquisition Corp. (DMAA) filed form 10-Q · 2026-08-14 · SEC EDGAR
- Drugs Made In America Acquisition Corp. (DMAA) filed form SCHEDULE 13G/A · 2026-08-14 · SEC EDGAR
- Drugs Made In America Acquisition Corp. (DMAA) filed form SCHEDULE 13G/A · 2026-08-14 · SEC EDGAR
- Drugs Made In America Acquisition Corp. (DMAA) filed form SCHEDULE 13G/A · 2026-08-13 · SEC EDGAR
- Drugs Made In America Acquisition Corp. (DMAA) filed form SCHEDULE 13G/A · 2026-08-13 · SEC EDGAR
Ask the AI about DMAA
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →